Latest news with #NasdaqListingRule5810
Business Upturn
3 days ago
- Business
- Business Upturn
Youxin Technology Ltd Receives Nasdaq Notifications Regarding Minimum Bid and Market Value of Listed Securities Requirements
Guangzhou, China, Aug. 15, 2025 (GLOBE NEWSWIRE) — Youxin Technology Ltd (Nasdaq: YAAS) (the 'Company' or 'Youxin Technology'), a software as a service ('SaaS') and platform as a service ('PaaS') provider committed to helping retail enterprises digitally transform their businesses, today announced that it received two staff determination notices (the 'Notice(s)') from the Listings Qualifications Department of The Nasdaq Stock Market LLC ('Nasdaq') on August 13, 2025. The Notices notify the Company that it is not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, and pursuant to Listing Rule 5550(b)(2), it is required to maintain a minimum Market Value of Listed Securities ('MVLS') of $35 million for continued listing on the Nasdaq Capital Market (the 'MVLS Requirement'). This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The Notices have no immediate effect on the listing of the Company's Class A ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker 'YAAS'. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until February 9, 2026 (the 'Bid Price Compliance Period'), to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Bid Price Compliance Period, the closing bid price per share of the Company's Class A ordinary shares is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance with the minimum bid price requirement by February 9, 2026, the Company may be eligible for an additional 180 calendar day grace period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, including by effecting a reverse stock split, if necessary. Pursuant to Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance period of 180 calendar days, or until February 9, 2026 (the 'MVLS Compliance Period'), to regain compliance with Nasdaq's MVLS Requirement. If at any time during the MVLS Compliance Period, the Company's MVLS is at least $35 million for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed. If the Company fails to regain compliance within the MVLS Compliance Period, the Company would have the right to a hearing before an independent panel. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process. The Company's business operations are not affected by the receipt of the Notices. The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and to remain listed on Nasdaq. About Youxin Technology Ltd Youxin Technology Ltd is a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses using its cloud-based SaaS product and PaaS platform to develop, use and control business applications without the need to purchase complex IT infrastructure. Youxin Technology provides a customized, comprehensive, fast-deployment omnichannel digital solutions that unify all aspects of commerce with store innovations, distributed inventory management, cross-channel data integration, and a rich set of ecommerce capabilities that encompass mobile applications, social media, and web-based applications. The Company's products allow mid-tier brand retailers to use offline direct distribution to connect the management team, distributors, salespersons, stores, and end customers across systems, apps, and devices. This provides retailers with a comprehensive suite of tools to instantly address issues using real-time sales data. For more information, please visit the Company's website: Forward-Looking Statements Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as 'approximates,' 'assesses,' 'believes,' 'hopes,' 'expects,' 'anticipates,' 'estimates,' 'projects,' 'intends,' 'plans,' 'will,' 'would,' 'should,' 'could,' 'may' or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC. References and links (including QR codes) to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. For more information, please contact: Youxin Technology Relations Department Email: [email protected]
Business Insider
13-06-2025
- Business
- Business Insider
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the 'Company') announced that it received a Staff delisting letter from The Nasdaq Capital Market ('Nasdaq') on May 20, 2025 indicating that the Company's failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the '10-Q') is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the 'Rule'). This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the 'Commission') on April 24, 2025, the Company received a deficiency notice from Nasdaq that the Company was not in compliance with Nasdaq's Listing Rules as set forth in the Rule given the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the '10-K'). As previously reported in the Current Report on Form 8-K filed with the Commission on April 18, 2025, the Company received a Staff delisting letter from the Nasdaq Listing Qualifications Staff indicating that, based upon the closing bid price of the Company's common stock, par value $0.00001 per share ('Common Stock'), from November 25, 2024 to January 10, 2025, the Company was no longer in compliance with the requirement for continued listing on The Nasdaq Capital Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the 'Minimum Bid Price Rule'). On April 14, 2025, Nasdaq issued a further notice to the Company that it determined that the Company's securities had a closing bid price of $0.10 or less for ten consecutive trading days and was subject to delisting pursuant to the provisions under Nasdaq Listing Rule 5810(c)(3)(A)(iii). As a result, unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the 'Panel'), trading of the Common Stock would be suspended at the opening of business on April 23, 2025, and a Form 25-NSE would be filed with the Commission, which would remove the Company's securities from listing and registration on Nasdaq. The Company timely requested a hearing before the Panel, which stayed the trading suspension pending the Panel's decision, and the Panel has scheduled a hearing date of May 27, 2025. As the Company is already before a Panel for its failure to comply with Minimum Bid Price Rule, the Company had seven calendar days from the date of the Notice, or until May 1, 2025, to request a stay of the suspension, which request will stay the suspension of the Company's securities pending the Panel's decision. The Company submitted a stay request on May 1, 2025. However, there can be no assurance that the Panel will grant the Company's request for a stay pending the hearing process or any further extension following the hearing. The Company intends to file the Form 10-K and 10-Q as promptly as possible in order to regain compliance with the Rule. About Onconetix, Inc.: Onconetix is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology. Through our acquisition of Proteomedix, we own Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union ('EU') under the In Vitro Diagnostic Regulation ('IVDR'). We also own ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia ('BPH'), a disorder of the prostate. For more information, visit Contact Information:
Business Insider
07-06-2025
- Business
- Business Insider
iOThree receives Nasdaq notification regarding minimum bid price deficiency
iOThree (IOTR) Limited announced that it has received a written notification from the Nasdaq Stock Market LLC on June 3, 2025, indicating that the Company was not in compliance with the $1.00 closing bid price requirement for the last 30 consecutive business days from April 21, 2025 to June 2, 2025 under the Nasdaq Listing Rule 5550(a)(2). This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The Nasdaq notification has no immediate effect on the listing of the Company's ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker 'IOTR'. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until December 1, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's ordinary shares must be at least $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period. Confident Investing Starts Here:
Business Insider
07-06-2025
- Business
- Business Insider
BloomZ granted 180-day extension by Nasdaq to regain compliance
BloomZ (BLMZ) announced it has received a letter form the Nasdaq Listing Qualification Staff granting it a second 180 calendar day period, or until December 1, 2025, to regain compliance with the minimum $1.00 per share bid price requirement for continued listing on The Nasdaq Capital Market, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(ii). The company was initially notified on December 2, 2024, that it did not meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and was provided 180 calendar days, or until June 2, 2025, to regain compliance. As the company was not able to regain compliance during the first compliance period, the Staff has determined that the company is eligible for an additional 180-day period to regain compliance. Confident Investing Starts Here:
Business Upturn
22-05-2025
- Business
- Business Upturn
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (the 'Company') announced that it received a Staff delisting letter from The Nasdaq Capital Market ('Nasdaq') on May 20, 2025 indicating that the Company's failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the '10-Q') is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the 'Rule'). This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the 'Commission') on April 24, 2025, the Company received a deficiency notice from Nasdaq that the Company was not in compliance with Nasdaq's Listing Rules as set forth in the Rule given the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the '10-K'). As previously reported in the Current Report on Form 8-K filed with the Commission on April 18, 2025, the Company received a Staff delisting letter from the Nasdaq Listing Qualifications Staff indicating that, based upon the closing bid price of the Company's common stock, par value $0.00001 per share ('Common Stock'), from November 25, 2024 to January 10, 2025, the Company was no longer in compliance with the requirement for continued listing on The Nasdaq Capital Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the 'Minimum Bid Price Rule'). On April 14, 2025, Nasdaq issued a further notice to the Company that it determined that the Company's securities had a closing bid price of $0.10 or less for ten consecutive trading days and was subject to delisting pursuant to the provisions under Nasdaq Listing Rule 5810(c)(3)(A)(iii). As a result, unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the 'Panel'), trading of the Common Stock would be suspended at the opening of business on April 23, 2025, and a Form 25-NSE would be filed with the Commission, which would remove the Company's securities from listing and registration on Nasdaq. The Company timely requested a hearing before the Panel, which stayed the trading suspension pending the Panel's decision, and the Panel has scheduled a hearing date of May 27, 2025. As the Company is already before a Panel for its failure to comply with Minimum Bid Price Rule, the Company had seven calendar days from the date of the Notice, or until May 1, 2025, to request a stay of the suspension, which request will stay the suspension of the Company's securities pending the Panel's decision. The Company submitted a stay request on May 1, 2025. However, there can be no assurance that the Panel will grant the Company's request for a stay pending the hearing process or any further extension following the hearing. The Company intends to file the Form 10-K and 10-Q as promptly as possible in order to regain compliance with the Rule. About Onconetix, Inc.: Onconetix is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology. Through our acquisition of Proteomedix, we own Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union ('EU') under the In Vitro Diagnostic Regulation ('IVDR'). We also own ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia ('BPH'), a disorder of the prostate. For more information, visit Contact Information: Onconetix, Inc.201 E. Fifth Street, Suite 1900Cincinnati, OH 45202 Phone: (513) 620-4101
